RxDoctor Payments Data

Gabriel Maislos

Podiatrist · Houston, TXNPI 1770681058

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,792 of the $7,817 with a category attached, or 61.3%. 31 manufacturers reported payments, led by Stryker at 26.3% of the total.

$7,817in general payments, 2019–2025

Across 103 payments — averaging $75.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$2K
  • Treace Medical Concepts, Inc.$2K
  • Musculoskeletal Transplant Foundation Inc.$1K
  • Endo USA, Inc.$916
  • Smith+Nephew$295
  • DJO, LLC$285
  • plus $2K from 25 others
$132,101in research payments, 2019–2025

Across 25 payments — averaging $5284.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Endo Pharmaceuticals Inc.$132K

What the payments were for

  • Consulting fees$1001%
  • Travel & lodging$2,92537%
  • Food & beverage$4,79261%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,817 in reported general payments places this provider in the 80th percentile of 470 podiatrist providers in Texas.

See all podiatrist providers in Texas

Medicare billing

Part B allowed, 2024
$581,669
Medicare patients
209
Services billed
4,240

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Clotrimazole29$731
Terbinafine Hcl12$268
Cephalexin34$159
Meloxicam11$23

Paid to pharmacies, not to this prescriber.

Other podiatrist in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →